Loading…
Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor
Minocycline, a second generation broad‐spectrum antibiotic, has been frequently postulated to be a “microglia inhibitor.” A considerable number of publications have used minocycline as a tool and concluded, after achieving a pharmacological effect, that the effect must be due to “inhibition” of micr...
Saved in:
Published in: | Glia 2016-10, Vol.64 (10), p.1788-1794 |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Minocycline, a second generation broad‐spectrum antibiotic, has been frequently postulated to be a “microglia inhibitor.” A considerable number of publications have used minocycline as a tool and concluded, after achieving a pharmacological effect, that the effect must be due to “inhibition” of microglia. It is, however, unclear how this “inhibition” is achieved at the molecular and cellular levels. Here, we weigh the evidence whether minocycline is indeed a bona fide microglia inhibitor and discuss how data generated with minocycline should be interpreted. GLIA 2016;64:1788–1794
Main Points
Minocycline is not a specific microglia inhibitor.
Minocycline has bona fide effects on neuroinflammation in vivo.
Data generated with minocycline are difficult to interpret. |
---|---|
ISSN: | 0894-1491 1098-1136 |
DOI: | 10.1002/glia.23007 |